Recent clinical studies have shown that therapy with bimekizumab, a dual IL-17A and IL-17F neutralizing antibody, resulted to pronounced clinical responses in patients with psoriasis (Oliver et al., 2022) and psoriatic arthritis (McInnes et al., 2023). Here, IL17A is linked to psoriasis.